CD8 T cells in CIN2–3 HPV-16-related lesions: a role in immune evasion

References

• de Sanjose S, Quint WG, Alemany L et al.; on behalf of the Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol.11, 1048–1056 (2010).
   PubMed Web of Science ®Google Scholar
• Einstein MH, Schiller JT, Viscidi RP et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect. Dis.9, 347–356 (2009).
   PubMed Web of Science ®Google Scholar
• Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am. J. Epidemiol.168(2), 123–137 (2008).
   PubMed Web of Science ®Google Scholar
• Castle PE, Rodríguez AC, Burk RD et al.; for the Proyecto Epidemiologico Guanacaste (PEG) Group. Short term persistence of human papillomavirus and risk of cervical precancer and cancer; population based cohort study. BMJ339, b2569 (2009).
   PubMedGoogle Scholar
• Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl Cancer Inst.102, 1478–1488 (2010).
   PubMedGoogle Scholar
• Trimble CL, Clark RC, Thoburn C et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J. Immunol.185, 7107–7114 (2010).
   PubMed Web of Science ®Google Scholar
• McCredie MR, Sharples KI, Paul C et al. Natural history of cervical neoplasia and risk of invasive caner in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol.9, 425–434 (2008).
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Stites DP, Patel S et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J. Infect. Dis.182(2), 595–598 (2000).
   PubMed Web of Science ®Google Scholar
• Welters MJ, de Jong A, van den Eeden SJ et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res.63(3), 636–641 (2003).
   PubMed Web of Science ®Google Scholar
• Trimble CL, Peng S, Thoburn C, Kos F, Wu TC. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol. Immunother.5, 799–803 (2010).
   Google Scholar
• Brun JL, Dalstein V, Leveque J et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am. J. Obstet. Gynecol.204(2), 169.e1–e8 (2011).
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med.361(19), 1838–1847 (2009).
   PubMed Web of Science ®Google Scholar
• van Seters M, van Beurden M, ten Kate FJ et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N. Engl. J. Med.358(14), 1465–1473 (2008).
   PubMed Web of Science ®Google Scholar
• Daayana S, Elkord E, Winters U et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br. J. Cancer102(7), 1129–1136 (2010).
   PubMed Web of Science ®Google Scholar
• Venuti A, Giovinazzi R, Sedati A, Badaracco G, Flamini S, Marcante ML. From latent HPV infection to high grade cervical squamous intraepithelial lesion in less than two years. Case report. Eur. J. Gynaecol. Oncol.14(6), 512–514 (1993).
   PubMedGoogle Scholar
• Schiffman M, Rodriguez AC. Heterogeneity in CIN3 diagnosis. Lancet Oncol.9(5), 404–406 (2008).
   PubMed Web of Science ®Google Scholar
• Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst. Rev.6, CD001318 (2008).
   Google Scholar
• Kyrgiou M, Koliopoulos G, Martin-Hirsch P et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet367(9509), 489–498 (2006).
   PubMed Web of Science ®Google Scholar
• Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol. Rev.239(1), 85–98 (2011).
   PubMed Web of Science ®Google Scholar
• Nieto K, Gissmann L, Schädlich L. Human papillomavirus-specific immune therapy: failure and hope. Antivir. Ther.15(7), 951–957 (2010).
   PubMedGoogle Scholar